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Abstract
Background: The objectives were to i) ascertain the cumulative risk of fatal or CCU treated COVID-19 in those
with diabetes and compare it to those without diabetes ii) among those with diabetes to investigate risk factors for,
and build a cross-validated predictive model of, fatal or CCU treated COVID-19.
Methods: In the total population of Scotland we ascertained all persons who had developed fatal or critical care
unit-treated COVID-19 (hereafter F/CCU-COVID-19) between 1st March and July 31st 2020 from the nationwide
virology, critical care unit, hospital discharge and register of deaths databases. Among those with F/CCU-COVID-19,
diabetes status was ascertained by linkage to the national diabetes register. The cumulative incidence of F/CCU-
COVID-19 in those with and without diabetes was compared using logistic regression. Among those with diabetes,
data on potential risk factors for F/CCU-COVID-19 were obtained from diabetes register and other linked health
administrative databases. Among those with diabetes we tested association of these factors with F/CCU-COVID-19
and constructed a prediction model using stepwise regression and 20-fold cross-validation.
Findings: 1082 (0.3%) of all those with diabetes in Scotland (n=319 349) developed F/CCU-COVID-19; the
age and sex adjusted odds ratio was [OR] 1.395 95% CI: 1.304-1.494, p<0.001 overall compared to the risk in total
population of Scotland without diabetes (n=4081 cases in 5 143 951 persons). The OR was 2.396 (1.815-3.163) in
type 1 and 1.369 (1.276-1.468) in type 2 diabetes. Of the 1082 persons with diabetes who developed F/CCU-COVID-
19, 90% were ≥60 years old. Among those with diabetes, adjusted for age, sex, diabetes duration and diabetes
type, those who developed F/CCU-COVID-19 were more likely to be male, live in residential care, or live in a
more deprived area, have a condition already listed as a COVID-19 risk condition such as heart or lung disease,
have retinopathy or reduced renal function, have worse glycaemic control, have a prior diabetic ketoacidosis or
hypoglycaemia hospitalisation in the past five years, be on more diabetes and other type of drugs, and to have been
a smoker (all p<0.001). Those with F/CCU-COVID-19 were less likely to be on an antihypertensive and had lower
systolic blood pressure than those without F/CCU-COVID-19 (both p<0.001). The relationship with BMI was
J-Shaped. The cross-validated predictive model of F/CCU-COVID-19 in those with diabetes, retained 11 factors in
addition to age, sex, diabetes type and duration and had a C-statistic of 0.85 (95% CI 0.83,0.86).
Interpretation: Overall risks of F/CCU-COVID-19 are substantially elevated in those with type 1 and type 2
diabetes compared to the background population. The risk of F/CCU-COVID-19, and therefore the need for special




Evidence before this study
We searched PubMed and the META database for studies examining risks of COVID-19 associated with diabetes
that had appropriate comparator populations and for studies exploring among those with diabetes what risk factors
predict COVID-19 using the terms (COVID-19 OR “novel coronavirus” OR SARS-CoV-2) AND diabetes, through
5th October 2020. Case-series have reported a high prevalence of diabetes among those hospitalised or a high
test-positivity rate for diabetes among those tested. However, diabetes is common, so to quantify the risk ratios for
COVID-19, comparison to the background population is needed. Only four such studies have reported; these found
relative risks of relative risks of 2.04 for type 2 diabetes and 3.5 for type 1 diabetes for COVID-19 hospitalised death
and 1.9 and 2.4 for COVID-19 hospitalisation and hospitalised death respectively for all diabetes in the others. The
range of potential determinants explored in these studies has been limited.
Added value of this study
In this study, we captured the data encompassing the first wave of the epidemic i.e. from March 1st 2020 when
the first case was identified to 31st July 2020 on which date infection rates had dropped sufficiently that shielding
measures were officially terminated. Including CCU treated and out of hospital deaths from COVID-19 for the first
time, as well as hospitalised deaths, we have shown that the risk of F/CCU-COVID-19 is increased 2.4-times in type 1
diabetes and 1.4-times in type 2 diabetes. For the first time we have shown that those with recent admissions history
for hypoglycaemia and diabetic ketoacidosis have an increased risk of severe or fatal disease. Ever smokers also
had increased risks. Prior specific comorbidities including heart disease, liver disease, and chronic lower respiratory
disease increased risk. We have shown for the first time that being exposed to more drug classes and having more
prior hospital admissions are markers of risk. A risk prediction model achieved a C-statistic of 0.85. We have
provided a Shiny app to give the reader a sense of how individual risk factor profiles in those with diabetes translate
into elevated risks compared to those without diabetes.
Implications of all the available evidence
During phases of the SARS-CoV-2 pandemic, when the effective reproduction number is high, those people with
diabetes most at risk may warrant special protection measures. A risk prediction score based on past history can
usefully identify those with diabetes most at risk and we provide an example of such a score.
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Background
Initial case series of people hospitalised with COVID-19 in several countries found over-representation of people
with diabetes[1–8]. More than a quarter of those admitted for COVID-19 in the UK had diabetes[9].
Just four studies, three from the UK, have compared risks in defined populations with and without diabetes
and all found increased risks in those with diabetes for in-hospital and total deaths[10–14]. Guidelines accordingly
describe all those with diabetes as being at elevated risk[8,15] but it is likely that among those with diabetes some are
at very high risk warranting special protection measures and that others not at much more risk than the background
population. As we enter the second wave of the epidemic a greater understanding of variation in COVID-19 risk in
those with diabetes is needed to tailor protection measures and inform vaccine strategies.
Only one study has explored determinants of risk of COVID-19 among those with diabetes to any extent with
Black and South Asian ethnicity, lower socioeconomic status, poorer glycaemic control and prior cardiovascular
disease reported to increase risks[13,14]. BMI was the only predictor of outcome of hospitalised COVID-19 beyond
age, sex and diabetes duration in a large French case series[16].
In this study we have used data from the first wave of the epidemic in Scotland i.e. from March 1st 2020 when
the first case was identified to 31st July 2020 on which date infection rates had dropped sufficiently that shielding
measures were officially terminated. For the total population of Scotland we aimed to i) compare the cumulative
risk of fatal or critical care unit treated (F/CCU) COVID-19 in all those with and without diabetes ii) among those
with diabetes, to ascertain which factors were associated with F/CCU-COVID-19 and iii) to build a cross-validated
risk prediction model. Our focus was on F/CCU-COVID-19 as rates of testing positive or being hospitalised with
COVID-19 are biased due to selective testing and hospitalisation policies.
Methods
The participants were the total population of Scotland (n=5 463 300) including all those with diabetes nationwide
(n=319 349) alive three weeks before the start of the epidemic in Scotland (estimated as Feb 7th 2020). The study
period was from March 1st 2020 to the 31st July 2020.
COVID-19 case ascertainment
For the total population of Scotland evidence of any detected COVID-19 was defined as having had a positive
RT-PCR test for SARS-CoV-2 or a hospital discharge code for COVID-19, or a COVID-19 code (U071 or U072)
anywhere on the death certificate. The databases used were the Electronic Communication of Surveillance in Scotland
(ECOSS) database that captures all NHS virology testing, the RAPID database of daily hospitalisations, the Scottish
Morbidity Records-01 of hospital discharges and the National Records of Scotland (NRS) death registrations data.
All such health related databases in Scotland are linkable as they all use the Community Health Index (CHI) unique
identifier. The CHI database also yielded data on age, sex, residential postcode, and residential care home status.
For all cases whether critical care had been provided was obtained by linkage to the Scottish Intensive Care Society
and Audit Group (SICSAG) database. Critical care included all admissions to intensive (ICU), high dependency
(HDU) or combined ICU/HDU care. Fatal COVID-19 was defined based on there being a U071 or U072 code
anywhere on the death certificate, OR any death within 28 days of testing positive. These are the official death
definitions used by National Register of Scotland and Public Health Scotland.
Diabetes database
To identify diabetes status among all those COVID-19 we linked the COVID-19 data to the national diabetes reg-
ister (Scottish Care Information (SCI)-Diabetes) and its associated research platform. As described elsewhere[17,18],
the diabetes research database has >99% coverage of all those with a diabetes diagnosis in Scotland. Inception into
SCI-Diabetes occurs when a diagnostic code for diabetes is assigned in primary or secondary care across Scotland.
Nightly uploads of key data items from primary, secondary and community clinical care into a federated national
health system (NHS) database follows. These data include diabetes type and clinical measurements such as body
mass index (BMI), blood pressure, laboratory results, smoking history and annual screening retinopathy grade
that we have used in our analysis. Regular extracts from this database are linked to other datasets including
hospitalisations (Scottish Morbidity Record (SMR) 01), dispensed prescriptions (Prescribing Information System-
PIS), renal registry, deaths and other routine datasets, using the CHI number then anonymised and imported into
the research platform. Records for all persons alive in the register at the start of the epidemic were used in this




All those with diabetes were assigned to which quintile of the residential postcode-based indicator, the Scottish
Index of Multiple Deprivation (SIMD), they belonged[19]. Self-assigned ethnic group and residential care home
status were captured from SCI-diabetes and CHI databases respectively.
Other morbidity and drug prescribing
From the diabetes research platform, all hospital discharge codes from SMR01 over the past five years and
Anatomical Therapeutic Chemical (ATC) codes[20] from PIS data for the past three years were extracted and used
to define co-morbid conditions and prior drug exposures. We derived history of a specific list of conditions and drug
classes that have been included as risk conditions for COVID-19 by public health agencies, hereafter termed “listed
conditions”[15] (see Supplement Methods for details of the codes used).
Statistical methods
Cumulative incidence of F/CCU-COVID-19 in those with and without diabetes between March 1st 2020 and July
31st 2020
For calculating cumulative incidence (risk) we used the age and sex specific counts of F/CCU-COVID-19 in those
with and without diabetes over the study period. The age and sex distribution of those with diabetes as of three
weeks before the first observed positive test nationally was available from SCI-Diabetes (n=319 349). To obtain
the at risk population for the population without diabetes we used the most recent publicly available one-year age
and sex band counts of the total Scottish population (Mid 2019 n=5 463 300) available from National Records of
Scotland[21]. We assumed these counts pertained at the start of the epidemic. From this, we subtracted the numbers
alive in the diabetes register in each sex specific age band to give the population without diabetes (n=5 143 951).
We summarised the relative difference in cumulative incidence of F/CCU-COVID- up to 31 July 2020 in those with
and without diabetes by sex as the odds ratio from a logistic regression model using one-year age band and sex
specific counts of cases and denominators.
Excess deaths
For the population with diabetes, the weekly counts of total deaths for the at risk population in each of the past
five years was available from the SCI-Diabetes research. We plotted the total number of deaths per week in 2020 in
those with diabetes along with the weekly average for the same week over the period 2015-2019 with the difference
representing excess deaths.
Associations of risk factors for F/CCU-COVID-19 among those with diabetes
Using the SCI-Diabetes research platform we first described sociodemographic variables, the “listed conditions”[15]
and potential vascular and diabetes specific risk factors in those with diabetes who did and did not develop F/CCU-
COVID-19. Association of each risk factor with F/CCU-COVID-19 was then reported adjusting for age, sex, diabetes
duration and type of diabetes using logistic regression. In total, associations of 35 variables were tested as listed in
Table 2. We report p-values unadjusted for multiplicity. Global P-values were calculated using a likelihood ratio test,
comparing models with and without the variable using R stats[22] ‘drop1’ function. For regression, missing variables
were imputed using chained equations assuming data were missing at random using the ‘Amelia’[23] package (see
supplement for details).
Construction of risk prediction model for F/CCU-COVID-19 among those with diabetes
Using the same data on 35 covariates, we constructed a multivariable risk prediction model of F/CCU-COVID-19
among those with diabetes. Age, sex, diabetes type, diabetes duration were fitted simultaneously as the baseline
model. The 35 covariates and interaction terms for age:sex, age:diabetes type, sex:diabetes type were made available
for selection into the final model. We used the mfp package in R[24,25] to first ascertain whether any of the
continuous variables should be fitted with any additional polynomial terms because of departure from linearity
(see supplement for details). We then used stepwise regression, alternating between forward and backward steps,
implemented in the R function stats::step, so as to maximize the Akaike Information Criterion (AIC), selecting any
additional potential factors as being predictive of F/CCU-COVID-19. The predictive performance of the base model
and then the final model were evaluated by 20-fold cross validation with performance calculated over all test folds as
the C-statistic and also as the expected information for discrimination using the wevid package (see supplement for
additional detail)[26].
The COVID-age for a person with diabetes can be defined as the age at which the risk of COVID-19 in a
non-diabetic individual of the same sex equates to the risk in the diabetic individual under study. This can be
derived from the final risk model in those with diabetes and the modelled risks in those without diabetes (see
supplement methods). To enable a user to calculate this COVID-age for a person with diabetes and a given set
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of characteristics, we generated a Shiny application located at https://diabepi.shinyapps.io/covidrisk/ (Online;
Accessed 11th November 2020). The purpose of the Shiny app to give the reader a sense of how individual risk factor
profiles in those with diabetes translate into elevated risks compared to those without diabetes (see supplement
for further details). This study is registered as an International Standard Randomised Controlled Trial number
ISCRTN45562523.
Results
Cumulative incidence (risk) of F/CCU-COVID-19 in those with and without diabetes 1 March to 31st July 2020
Risk and excess death in those with diabetes
Among those 319 349 persons in the population with diabetes at the start of the epidemic, by 31st July 2020
2724 had any evidence of COVID-19. Of the 2724 persons with any evidence of COVID-19, 1082 had developed
F/CCU-COVID-19 (0.3% of all those with diabetes) of whom 963 died. More details of case ascertainment and
severity ascertainment is given in Supplement (Supplement Figure 1 and associated Supplement Results text).
Table 1 shows the distribution of risk of F/CCU-COVID-19 in the population with diabetes. The risk of
F/CCU-COVID-19 increased with age. Just 30 of 1082 with F/CCU-COVID-19 were below age 50 years (all of
these were age >20 years). The overall risk was 0.4% in males and 0.3% in females. Overall, 0.1% of those with type
1 and 0.4% of those with type 2 diabetes developed F/CCU-COVID-19.
Figure 2 shows the total deaths among those with diabetes in every 7 day-window since 1/1/2020 plotted against
the average number of deaths in that same seven day interval in 2015-19. The difference in these two is excess deaths
during the period. The grey zone depicts how much was attributable to COVID-19. Total deaths exceeded the
average from early March and returned to the average by early June. Altogether in this first wave of the epidemic
between March 1st and July 31st 2020 there were 1228 excess deaths in comparison to the average for this period in
the preceding years. Of these, 963 (78.45%) were due to COVID-19.
Comparison of risk in those with and without diabetes
In the total population of Scotland without diabetes (n=5 143 951) 4081 (0.08%) developed F/CCU-COVID-19
in the same period (Supplement Table 1). Figure 1 shows the risk of F/CCU-COVID-19 in those with and without
diabetes by sex. The diabetes associated increase in risk was apparent in both sexes and at all age bands.
Adjusted for age and sex in a logistic regression, as of 31st July 2020, diabetes was associated with an odds ratio
of 1.395 (95% CI 1.304-1.494, p<0.001) for F/CCU-COVID-19 with similar odds ratio found in males and females
(Supplement Table 2). The OR was 2.396 (1.815-3.163) in type 1 and 1.369 (1.276-1.468) in type 2 diabetes. There
was a statistically significant interaction between diabetes and age on risk of F/CCU-COVID-19 (p<0.001) with the
OR being 2.494 (2.032- 3.061) for those age 0-59, 1.764 (1.457-.2.136) for those 60-69 years and 1.327 (1.227-1.434)
in those aged 70 upwards for example. When the analysis was limited to various time points since the start of
the epidemic the OR associated with diabetes was highest at end of March 1.770 (1.566-2.002) and fell to 1.446
(1.343-1.557) by end of Aril and then to the July 31st value of 1.395 (1.304-1.494).
Associations of risk factors with F/CCU-COVID-19 among those with diabetes
Table 2 shows the crude unadjusted characteristics of those with diabetes who did and did not develop F/CCU-
COVID-19. Supplementary Tables 3 and 4 show these data by type of diabetes. Table 3 shows the odds ratios for
F/CCU-COVID-19, 95% confidence intervals and p-values for age, sex, diabetes type and duration and then for
each other risk factor separately adjusted for age, sex diabetes type and duration. The comments below are based
on these adjusted data. Data for continuous variables divided into categories including missingness are given in
Supplementary Tables 5 and 6.
Sociodemographic factors
As shown in Table 3 older age, male sex and longer diabetes duration were all associated with statistically
significant increased risk of F/CCU-COVID-19. Adjusted for these factors, the type of diabetes was not associated
with any statistically significant difference in risk. Living in a residential care home was associated with very
large and statistically significant increased risk of F/CCU-COVID-19 (OR 16.570, 95% CI 14.326, 19.165 p<0.001).
Sociodemographic (SIMD) quintile showed a strong statistically significant gradient in risk falling from the most to
least deprived quintile. There was no statistically significant variation in risk by ethnic group. Note however, that
the prevalence of non-White ethnicities in this diabetes population (Table 2) is too low, commensurate with the
background general population of Scotland, to have any power to detect ethnic variation in COVID-19 risk among
those with diabetes.
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Co-morbid conditions and clinical factors
As shown in Table 3, the number of prior hospitalisations for hypoglycaemia, diabetic ketoacidosis and for reasons
other than these over the past five years was strongly associated with F/CCU-COVID-19. Each of the co-morbid
conditions listed as risk conditions for COVID-19 showed strong, highly statistically significant associations with
F/CCU-COVID. Risk increased with increasing HbA1c. There was no statistically significant linear relationship
between BMI and disease (OR 1.002, 95% CI 0.991, 1.013, p=0.706, Table 3). However, the multivariable fractional
polynomials analysis revealed evidence for a statistically significant non-linear J-shaped relationship with BMI (See
Supplement Figure 2 for a plot of the relationship from the mfp analysis). Those who developed F/CCU-COVID-19
had statistically significantly lower systolic blood pressure than those who did not. Being on any antihypertensive
was associated with a statistically significantly lower risk of F/CCU-COVID-19 (OR 0.801, 95% CI 0.705, 0.909
p=0.001). More detailed exploration of type of antihypertensives (see Supplement Tables 5 and 6) showed that
the point estimate for the OR for each antihypertensive subclass was below 1, other than for the rarely used
“centrally-acting” class. In those who developed F/CCU-COVID, eGFR was statistically significantly lower and
prevalence of albuminuria was higher than those who did not. Having retinopathy was statistically significantly
associated with developing F/CCU-COVID-19. Having a history of smoking was associated with a significantly
increased risk of F/CCU-COVID-19 though risk was not statistically significantly higher in current versus never
smokers.
Statistically significant increased risks were found in recipients versus non-recipients of several drug classes
including non-steroidal anti-inflammatory drugs, proton-pump inhibitors and anti-coagulants. The more diabetes
drug subclasses used in the past three years, the greater the risk of F/CCU-COVID-19 disease. Having been on
insulin or sulphonylureas was associated with the highest risks (Supplement Table 6). As shown in Table 3 the
number of different types of drugs other than those used for diabetes that the person had been exposed to in the
past three years was strongly associated with F/CCU-COVID.
Distribution of characteristics in those with and without F/CCU-COVID-19 by type of diabetes is given in
Supplement Tables 3 and 4. Broadly the same pattern of associations is found in both type 1 and type 2 diabetes.
The main differences were that DKA and hypoglycaemia admission rates, and the differences between those with
and without F/CCU-COVID-19 were greater, for type 1 diabetes than type 2. A sensitivity analysis restricted to
the fatal cases showed the same pattern of associations as was found for F/CCU-COVID-19.
Risk prediction model for F/CCU-COVID-19 among those with diabetes
Table 4 shows the final set of covariates retained in the stepwise selection model, on top of age, sex, diabetes type
and duration which were entered as fixed covariates. The multivariable fractional polynomials analysis indicated
that the association with number of hospital admission was best entered into the model as log (admissions) and that
terms for both BMI and log BMI should be included. Note that selection is based on the AIC not p-values. Terms for
interactions between age and type of diabetes, sex and type, and age by sex were not selected. The C-statistic for the
baseline model containing just age, sex, diabetes type and duration was 0.76 (95% CI:0.75-0.76). The cross-validated
stepwise model retained a further 11 factors and had a C-statistic of 0.85 (95% CI:0.83-0.85) (Supplement Figure
3). The cross-validated model was well calibrated (Supplement Figure 4) and the Hosmer Lemeshow test was not
statistically significant at p=0.378.
The Shiny app that uses the prediction model and the risk data in the population without diabetes to return the
COVID-age can be found at https://diabepi.shinyapps.io/covidrisk/ (Online; Accessed 11th November 2020).
Discussion
Risk of F/CCU-COVD-19 in diabetes
This report highlights the elevation in risk of F/CCU-COVID-19 with diabetes. The elevation in risk relative to
the population without diabetes adjusted for age and sex was higher for type 1 (2.4 times) type 1 than for type 2
(1.4-times). This greater elevation in type 1 diabetes is likely accounted for by longer duration of diabetes since in
the older age bands cumulative incidence was higher in type 1 than type 2 and since, among those with diabetes, no
significant difference in risk by type was found once age, sex and diabetes duration were adjusted for. The lower
overall age distribution in type 1 than type 2 diabetes and the strong association of older age with risk however
meant that overall a lower proportion of those with type 1 than type 2 developed F/CCU-COVID-19. Although
there were no cases of F/CCU-COVID-19 under age 20 years in those with diabetes, above this age an elevation in
the risk associated with diabetes was apparent.
In terms of absolute risk three people with diabetes in every 1000 developed F/CCU-COVID-19 up to July 2020.
The impact on the weekly deaths was clearly discernable and peaked in early April. Of note the excess was not all
explained by COVID-19 designated deaths; this may represent under-ascertainment of COVID-19 deaths but may
also reflect the knock on effect on health services of the epidemic[27].
6
We focused on F/CCU-COVID-19 rather as the probability of being tested or hospitalised for any given level of
symptoms could easily vary by diabetes status leading to observation bias. Another important potential bias might
be termed “at risk bias”. Diabetes was named early in the epidemic as a moderate risk condition. Thus people with
diabetes may have adopted social distancing measures more stringently than those without diabetes which could
bias the odds ratio downwards. Indeed, consistent with this, when the analysis was limited to various time points
since the start of the epidemic the OR associated with diabetes was highest at end of March 1.770 (1.566-2.002)
falling to 1.395 (1.304-1.494) by end July. Depletion of the most susceptible early in the epidemic could also cause
the odds ratio to fall over time this since the susceptibility is higher in those with diabetes. However, we have no
direct data to prove these potential explanations.
There are few other studies with general population denominators allowing the relative risk of COVID-19 in
those with diabetes relative to the background population to be estimated. In the OpenSAFELY study primary
care records in England were linked to death certification records. The age, sex-adjusted OR for COVID-death
associated with diabetes was 1.6 for those with an HbA1c < 58 mmol/mol and was 2.6 for those with HbA1c above
this level. Type of diabetes was not differentiated[11]. An analysis of the UkBiobank study diabetes was associated
with a relative risk of 1.91 for COVID-19 hospitalisation[28]. In the English National Audit cohort[13,14] risk ratios
of COVID-19 death for type 1 and type 2 diabetes were 3.51 and 2.03 and were attenuated in Whites (3.06 for
type 1 and 1.91 for type 2). In a matched case control study of the total population of Scotland from earlier in
the epidemic and not including cases derived solely from hospital admissions (as these weren’t yet available) we
reported slightly higher conditional odds ratios of 2.75 (1.96-3.88) for type 1 and 1.60 for type 2 ( 1.48-1.74)[29]. All
these studies are therefore consistent in finding elevations in risk for type 1 and type 2 diabetes in the same range.
However, the OR for diabetes will vary somewhat depending on the stage of the epidemic and with the ethnicity
distribution as well as whether out of hospital deaths are captured. Studies that do not capture out of hospital
deaths may preferentially omit older cases and will report a higher summary OR since the OR varies with age.
Risk factors association with F/CCU-COVID-19 in diabetes
We found that risk of F/CCU-COVID-19 rose steeply with age and was higher in males as has been reported
in many other populations[30]. More than a third of those with diabetes who developed F/CCU-COVID-19 lived
in residential care homes emphasizing the critical importance of protecting such vulnerable individuals during the
remainder of this epidemic. There was a strong socioeconomic gradient.
We showed that adjusted for age, sex, diabetes duration those who developed F/CCU-COVID-19 on average had
worse profiles for almost every clinical measure we examined; they were more likely to have other co-morbidities
and evidence of diabetic microvascular disease (with more impaired renal function and retinopathy). On average
they had worse glycaemic control, were more likely to have had a prior diabetic ketoacidosis or hypoglycaemia
hospitalisation and other hospitalisations in the past five years. They were on more diabetes and non-diabetes drugs.
We also found strong associations with NSAIDS and proton pump inhibitors which are among the most commonly
prescribed drugs and are often markers of polypharmacy. They were more likely to have smoked. We found a J
shaped relationship with BMI. Surprisingly, although strong associations of hypertension with COVID-19 have been
reported elsewhere[5–7], we found that those who developed F/CCU-COVID-19 had slightly lower blood pressures
than those who did not and that being on anti-hypertensives was associated with a lower risk than not being on any
antihypertensive. Among the specific anti-hypertensive drug classes thiazides and angiotensin II receptor antagonists/
blockers had the lowest odds ratios for F/CCU-COVID-19.
Similar associations of age, sex diabetes duration, socioeconomic status, prior CVD, renal status, blood pressure
and glycaemic control with COVID-19 death were found in the English National Audit study[13,14]. In that
study non-white ethnicity was found to be associated with COVID-19 death whereas in Scotland the prevalence of
non-White ethnic groups is too low to allow detection of any ethnic differences in COVID-19; just 2.9% of those with
diabetes are known to be of South Asian origin and 0.5% of Black origin. We found that being on antihypertensive
drugs was associated with a lower risk but they found an increased risk. However, that higher risk was driven by a
large effect in South Asian and Mixed ethnicity groups and was not seen in whites or other ethnic groups. The
U-shaped association with BMI in the English Audit Study was stronger than the J-shaped relationship we found.
This difference is likely also driven by the different ethnic mix in the studies since the relationship of higher BMI to
higher risk was most apparent in those of non-White ethnicity in the English Audit Study. The increased risk at
lower BMI including underweight in both studies likely reflects comorbid effects related to F/CCU-COVID-19 that
are associated with weight loss. Given the elevation in BMI among people with type 2 diabetes, it would not be
surprising to see such comorbid effects resulting in the nadir of the curve being around the average BMI of 30kg/m2
as was found here. In the English Audit Study, as in ours, ex-smokers were at increased risk but they reported that
current smokers were at reduced risk, but we did not. This difference may reflect that their smoking effects were
reported adjusted for all other variables including possible mediators such as CVD. The extensive data on other
factors we examined were not evaluated in the English Audit Study.
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Such minimally adjusted associations that we have reported are useful as a prelude to building the predictive
model of F/CCU-COVID-19 discussed further below. They are also useful for suggesting possible causal mechanisms.
Thus the SIMD differential may be partly mediated through higher levels of smoking, and worse glycaemic control
and onward effects on CVD and other co-morbidities but may also relate to other unmeasured factors determining
infection such as overcrowding or occupation. However much more extensive modelling methods[31] are needed to
infer causality for each of the associated factors and is out of scope here. Such methods are especially needed to
understand drug associations which are hugely susceptible to confounding by indication. Meanwhile it is worth
considering which of the associations we report, if causal, would be modifiable. Improved protection in residential
care homes, smoking cessation, improved glucose control, reduction of BMI, optimised management of comorbidities,
medication reviews of polypharmacy are possible interventions to reduce risk suggested by these analyses but require
formal analysis. It is interesting that the data suggest protective effects of anti-hypertensives but this also requires
more detailed causal analyses.
Prediction model and estimation of COVID-age
We obtained a reasonable predictive accuracy in our multivariable model with a C-statistic of 0.85; thus faced
with a case and non-case pair the model would correctly assign the case as being at higher risk 85% of the time. This
level of predictive accuracy disproves the notion all those with diabetes are of similar risk. The variables retained
variables in the model are those that are most predictive and not necessarily causal; some of the most valuable
predictors include the number of prior hospital admissions in past five years, number of diabetes drugs and number
of non-diabetes drugs which were not evaluated in other diabetes COVID-19 studies.
The absolute risk of F/CCU-COVID-19 will mostly reflect the stage of the epidemic and the current effective
R number in the population[32]. Accordingly we have produced the Shiny app to convert the absolute risk score
produced by the prediction model to the COVID-age i.e. the age at which the same absolute risk was observed in
a person of the same sex in the population without diabetes at the same stage of the epidemic. This concept of
COVID-age is becoming increasingly used in occupational health[33] and is more interpretable than scores that
produce absolute risks such as the QCOVID score[34]. COVID-age should be less susceptible to the prevailing R
than absolute risk but we will monitor the need the need to recalibrate the underlying models as the pandemic
unfolds.
Limitations and advantages
Some key strengths of our study are the total population coverage, the inclusion of out-of-hospital deaths, the
inclusion of those who might have died without CCU, the much more extensive exploration of potential prior risk
factors than conducted previously and the development of the shiny app for COVID-age. Limitations of our study
are potential biases noted above and that we, as others, lack quality control data on assignation of COVID-19
deaths. Furthermore we lack the detailed clinical data needed to define severe cases according to the World Health
Organisation criteria[35] or to capture all possible co-morbidities. Another limitation is that we had to make an
assumption age and sex bands population numbers won’t have changed much between mid-2019 and the start of the
epidemic in Feb/March 2020. This is however a very reasonable assumption: between 2018 and 2019 the overall
change in the Scottish population size was just +0.5% with no change in those aged 75+ years[21]. An important
limitation is that we have not been able access any other datasets in which to externally validate the risk prediction
model. Therefore, its presentation here is primarily to facilitate an understanding of the magnitude of increase
in risk that occurs with different risk factor combinations that is not easily intuited from looking a table of odds
ratios associated with specific risk factors or markers. We also hope that it serves as an illustration to those in other
countries of an approach they might usefully adopt that could help those with diabetes and their clinicians to make
shielding decisions during the rest of the epidemic. It is likely that our data are relevant to many developed settings
but in developing countries the background mix of other infectious and non-infectious diseases among those with
diabetes may vary considerably. Also, for many countries, the low prevalence of non-White people in our population
means that potentially important ethnicity effects that may pertain are not represented in our model.
Policy Implications
Both type 1 and type 2 diabetes are associated with substantial increases in the risk of COVID-19 disease
compared with the risks seen in people of the same age in the background population. However, it is important
to consider the absolute number of persons with diabetes in our population that have developed severe or fatal
disease; 3 in 1000 persons have had fatal or CCU treated disease. We have shown that among those with diabetes
risk of severe disease varies widely and is predictable. This should inform shielding policies and vaccine prioritisation
strategies. The Shiny app has been provided for illustrative purposes only to allow a greater understanding of how a
prediction model broadly translates into COVID-age in individuals with diabetes. External validation, regulatory
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Figure 1: Risk of F/CCU-COVID-19 in the National population of Scotland with and without diabetes by age band and sex by 31st July
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Figure 2: Weekly deaths from from all causes and from causes other than COVID-19 in people with Diabetes in Scotland during 2020
compared with average deaths in that week from 2015 to 2019
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Table 1: Cumulative incidence of F/CCU-COVID-19 in the Scottish population with diabetes, by age, sex and diabetes type by 31st July
2020
Age Band (years) 0-39 40-49 50-59 60-69 70-79 80+ Total
All 22264 24863 58438 81606 80909 51269 319349
F/CCU-COVID-19 5(0.0) 25(0.1) 80(0.1) 134(0.2) 306(0.4) 532(1.0) 1082(0.3)
Male 11821 14402 34968 49001 46201 24093 180486
F/CCU-COVID-19 2(0.0) 15(0.1) 54(0.2) 99(0.2) 206(0.4) 281(1.2) 657(0.4)
Female 10443 10461 23470 32605 34708 27176 138863
F/CCU-COVID-19 3(0.0) 10(0.1) 26(0.1) 35(0.1) 100(0.3) 251(0.9) 425(0.3)
Type 1 14732 5747 6333 4486 2227 858 34383
F/CCU-COVID-19 2(0.0) 5(0.1) 10(0.2) 7(0.2) 14(0.6) 13(1.5) 51(0.1)
Type 2 6507 18072 50273 75031 76792 49285 275960
F/CCU-COVID-19 2(0.0) 17(0.1) 68(0.1) 125(0.2) 285(0.4) 511(1.0) 1008(0.4)
Other 1025 1044 1832 2089 1890 1126 9006
F/CCU-COVID-19 1(0.1) 3(0.3) 2(0.1) 2(0.1) 7(0.4) 8(0.7) 23(0.3)
Data are shown in N or N(%)
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Table 2: Characteristics of all those with diabetes in Scotland who did and did not develop F/CCU-COVID-19 by 31st July 2020
No F/CCU-COVID-19 F/CCU-COVID-19 Total diabetes population
Total included 318267(99.66) 1082(0.34) 319349
Sociodemographic
Age (years) 66.7(56.3,75.8) 79.9(71.4,85.7) 66.7(56.3,75.8)
Diabetes duration (years) 10.5(5.7,16.6) 13.5(8.0,19.2) 10.5(5.7,16.6)
Carehome resident 5897(1.9) 397(36.7) 6294(2.0)
Deprivation index
Quintile 1 (most deprived) 73188(23.0) 322(29.8) 73510(23.0)
Quintile 2 71102(22.3) 264(24.4) 71366(22.3)
Quintile 3 63401(19.9) 188(17.4) 63589(19.9)
Quintile 4 56203(17.7) 173(16.0) 56376(17.7)
Quintile 5 (least deprived) 46251(14.5) 102(9.4) 46353(14.5)
Unknown 8122(2.6) 33(3.0) 8155(2.6)
Ethnicity
White 237205(74.5) 870(80.4) 238075(74.6)
South Asian 9218(2.9) 16(1.5) 9234(2.9)
Black 1589(0.5) 5(0.5) 1594(0.5)
Chinese 1205(0.4) 4(0.4) 1209(0.4)
Other 12103(3.8) 30(2.8) 12133(3.8)
Unknown 56947(17.9) 157(14.5) 57104(17.9)
Comorbidities
Any DKA admission in past 5 years 6623(2.1) 23(2.1) 6646(2.1)
Any hypoglycaemia admission in past 5yrs 5769(1.8) 73(6.7) 5842(1.8)
No. of other hospital admissions in past 5 years 1.0(0.0,3.0) 5.0(2.0,11.0) 1.0(0.0,3.0)
Any heart disease 100482(31.6) 696(64.3) 101178(31.7)
Asthma or chronic lower airway disease 105066(33.0) 504(46.6) 105570(33.1)
Neurological and dementia (excluding epilepsy) 15076(4.7) 232(21.4) 15308(4.8)
Liver disease 3075(1.0) 29(2.7) 3104(1.0)
Immune disease or on immunosuppressants 4078(1.3) 24(2.2) 4102(1.3)
Any listed condition 165813(52.1) 896(82.8) 166709(52.2)
Other clinical measures
Insulin pump use 4811(1.5) 1(0.1) 4812(1.5)
Flash glucose monitor use 11711(3.7) 6(0.6) 11717(3.7)
HbA1c (mmol/mol) 57(49,70) 58(47,71) 57(49,70)
BMI (kg/m2) 30(27,35) 29(25,33) 30(27,35)
Systolic BP (mmHg) 134(124,142) 132(122,142) 134(124,142)
Diastolic BP (mmHg) 77(70,82) 74(67,80) 77(70,82)
Total cholesterol (mmol/L) 4(4,5) 4(3,5) 4(4,5)
eGFR (mL/min/1.73m2) 83(65,97) 64(44,82) 83(65,97)
Albuminuric status
Normal 131192(41.2) 300(27.7) 131492(41.2)
Micro 55417(17.4) 235(21.7) 55652(17.4)
Macro 11353(3.6) 77(7.1) 11430(3.6)
Unknown 120305(37.8) 470(43.4) 120775(37.8)
Retinopathy
None 200428(63.0) 618(57.1) 201046(63.0)
Non referable 48624(15.3) 160(14.8) 48784(15.3)
Referable / eye clinic 28170(8.9) 134(12.4) 28304(8.9)
Unknown 41045(12.9) 170(15.7) 41215(12.9)
Tobacco smoking status
Current smoker 50734(15.9) 111(10.3) 50845(15.9)
Ex smoker 153181(48.1) 679(62.8) 153860(48.2)
Never smoked 111292(35.0) 287(26.5) 111579(34.9)
Unknown 3060(1.0) 5(0.5) 3065(1.0)
Drug exposures
Lipid lowering 210701(66.2) 806(74.5) 211507(66.2)
Proton Pump Inhibitors 132581(41.7) 582(53.8) 133163(41.7)
NSAIDS 143947(45.2) 698(64.5) 144645(45.3)
Anti-coagulants anti-platelets 112983(35.5) 667(61.6) 113650(35.6)
Antihypertensives (any) 198117(62.2) 713(65.9) 198830(62.3)
Number of ATC level 3 drug classes (excluding
DM)
8.0(4.0,12.0) 11.0(8.0,15.0) 8.0(4.0,12.0)
Number of DM drug classes prescribed 1.0(1.0,2.0) 1.0(1.0,2.0) 1.0(1.0,2.0)
Data are shown in N(%) for categorical values and median interquartile range for continuous values
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Table 3: Logistic regression of association of characteristics with having F/CCU-COVID-19 in people with diabetes. Diabetes duration
was adjusted for age. Sex and diabetes type were adjusted for age and diabetes duration. All other associations were adjusted for age,
sex, diabetes duration and diabetes type.
Predictor Odds Ratio 95%CI P-Value
Age (years) 1.076 (1.071, 1.082) <0.001
Sex (global) <0.001
Male 1 (reference)
Female 0.705 (0.623, 0.798) <0.001
Diabetes type (global) 0.693
Type 2 diabetes 1 (reference)
Type 1 diabetes 1.087 (0.789, 1.498) 0.610
Other diabetes types 0.869 (0.574, 1.317) 0.509
Diabetes duration (years) 1.016 (1.009, 1.022) <0.001
Carehome resident 16.570 (14.326, 19.165) <0.001
Any hypoglycaemia admission in past 5yrs 3.178 (2.480, 4.072) <0.001
Deprivation index (global) <0.001
Quintile 1 (most deprived) 1 (reference)
Quintile 2 0.732 (0.622, 0.862) <0.001
Quintile 3 0.545 (0.455, 0.653) <0.001
Quintile 4 0.556 (0.462, 0.669) <0.001
Quintile 5 (least deprived) 0.379 (0.303, 0.473) <0.001
Ethnicity (global) 0.086
White 1 (reference)
South Asian 0.616 (0.368, 1.033) 0.066
Black 1.770 (0.727, 4.311) 0.209
Chinese 0.784 (0.267, 2.295) 0.656
Other 0.740 (0.513, 1.066) 0.106
Any DKA admission in past 5 years 2.869 (1.846, 4.460) <0.001
Any hypoglycaemia admission in past 5yrs 3.178 (2.480, 4.072) <0.001
Ever admitted to hospital in past 5 years 3.307 (2.789, 3.922) <0.001
Any heart disease 2.425 (2.135, 2.754) <0.001
Asthma or chronic lower airway disease 1.691 (1.500, 1.907) <0.001
Neurological and dementia (excluding epilepsy) 3.810 (3.284, 4.421) <0.001
Liver disease 3.021 (2.082, 4.384) <0.001
Immune disease or on immunosuppressants 2.334 (1.552, 3.510) <0.001
Any listed condition 3.167 (2.701, 3.713) <0.001
Insulin pump use 0.330 (0.046, 2.372) 0.271
Flash glucose monitor use 0.414 (0.176, 0.973) 0.043
HbA1c (mmol/mol) 1.010 (1.006, 1.014) <0.001
BMI (kg/m2) 1.002 (0.991, 1.013) 0.706
Systolic BP (mmHg) 0.986 (0.982, 0.990) <0.001
Diastolic BP (mmHg) 0.994 (0.987, 1.001) 0.074
Total cholesterol (mmol/L) 1.035 (0.974, 1.100) 0.267
eGFR (mL/min/1.73m2) 0.992 (0.988, 0.995) <0.001
Albuminuric grade (global) <0.001
Normal 1 (reference)
Micro 1.352 (1.155, 1.583) <0.001
Macro 1.922 (1.519, 2.430) <0.001
Retinopathy grading (global) <0.001
None 1 (reference)
Non referable 1.161 (0.975, 1.382) 0.094
Referable or eye clinic 1.672 (1.377, 2.032) <0.001
Tobacco smoking (global) 0.001
Never smoked 1 (reference)
Ex smoker 1.296 (1.126, 1.491) <0.001
Current smoker 1.133 (0.907, 1.416) 0.270
Any lipid lowering 1.126 (0.981, 1.293) 0.091
Any proton pump inhibitor 1.412 (1.252, 1.593) <0.001
Any NSAID 1.848 (1.630, 2.097) <0.001
Any anticoagulants 1.663 (1.466, 1.887) <0.001
Any antihypertensive 0.801 (0.705, 0.909) 0.001
Number of ATC level 3 drug classes (excluding DM) 1.079 (1.068, 1.091) <0.001
Number of DM drug classes prescribed 1.139 (1.083, 1.199) <0.001
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Table 4: Stepwise logistic regression of association of characteristics with F/CCU-COVID-19 in people with diabetes.
Predictor Odds Ratio 95% CI P-Value
Age (years) 1.044 (1.036, 1.051) <0.001
Sex (global) <0.001
Male 1 (reference)
Female 0.535 (0.470, 0.608) <0.001
Diabetes type (global) 0.618
Type 2 diabetes 1 (reference)
Type 1 diabetes 1.119 (0.806, 1.553) 0.501
Other diabetes types 0.866 (0.567, 1.321) 0.504
Diabetes duration (years) 0.998 (0.990, 1.006) 0.595
Carehome resident 10.828 (9.251, 12.675) <0.001
Deprivation index (global) <0.001
Quintile 1 (most deprived) 1 (reference)
Quintile 2 0.848 (0.718, 1.002) 0.052
Quintile 3 0.619 (0.514, 0.744) <0.001
Quintile 4 0.656 (0.542, 0.793) <0.001
Quintile 5 (least deprived) 0.484 (0.385, 0.607) <0.001
log(No. of other hospital admissions + 1 (5yrs)) 1.595 (1.481, 1.717) <0.001
Neurological and dementia (excluding epilepsy) 1.273 (1.081, 1.499) 0.004
HbA1c (mmol/mol) 1.005 (1.001, 1.009) 0.008
BMI (kg/m2) 1.091 (1.047, 1.136) <0.001
log(BMI (kg/m2)) 0.080 (0.022, 0.291) <0.001
eGFR (mL/min/1.73m2) 0.992 (0.989, 0.995) <0.001
Systolic BP (mmHg) 0.994 (0.990, 0.998) 0.004
Any antihypertensive 0.792 (0.687, 0.913) 0.001
Number of DM drug classes prescribed 1.065 (1.004, 1.129) 0.036
Number of ATC level 3 drug classes (excluding DM) 1.027 (1.013, 1.041) <0.001
Age, sex, diabetes duration and type of diabetes were entered as the baseline model. The remaining
variables were retained by the stepwise procedure using the Akaike information criterion. The C-Statistic
(95%CI) for the base and full models were 0.76(0.75,0.77) and 0.85(0.83,0.86) respectively. The
expected information for discrimination Λ was 0.75 bits for the base model and 1.54 for the full model.




Derivation of variables used from the SCI-Diabetes research platform
Clinician assigned diabetes type in SCI-Diabetes was accepted unless contradicted by available data on age
at diagnosis and prescription history. Those who were assigned type 1 were reassigned as type 2 if they had a
contradictory drug history and age at diagnosis >40 years. A prescription history that contradicts type 1 diabetes
was more than 1-year of non-metformin oral diabetes drug use or more than a 1-year interval from diagnosis to insulin.
This rule reassigned 10.8% of type 1 diabetes as type 2. Those who were initially assigned as type 2 were reassigned
to type 1 only if they have insulin from diagnosis and an age of onset below age 30 years (0.8% were reassigned).
Smoking was categorised according to the categories in the electronic health record front end to SCI-Diabetes;
never/current/ex or unknown. Albuminuria was defined based on urinary albumin concentration in urines collected
at routine clinic visits and categorised as normo-, micro- or macroalbuminuric according to the albumin/creatinine
ratio (ACR) falling in the intervals 0–3.39 mg/mmol, 3.39–33.9 mg/mmol, or above 33.9 mg/mmol, based on two
out of three most recent consecutive measurements. Retinopathy was defined based on grading of most recent retinal
image at screening and categorised as none; non referable which is mild background; referable or at clinic which is
pre-proliferative or worse retinopathy or maculopathy or prior referral to eye clinic because of retinopathy.
The Scottish Index of Multiple Deprivation (SIMD) ranks geographic areas by a single index capturing seven
domains of deprivation and is summarised in quintiles. Here, for those with diabetes postcode of residence obtained
from the CHI database was assigned to the SIMD quintile it belonged and was used as a measure of socioeconomic
status. Residential care home status for those with diabetes was available via the care home flag for postal address
in the CHI database
ICD-10 Hospital Discharge codes from Scottish Morbidity Record-01 and ATC Drug codes from Prescribing Informa-
tion System used for deriving “Listed conditions”
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Grouping BNF ATC regex ICD10 ICD10 Regex OPCS4 Code OPCS4 Regex 
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G10-G14 Systemic atrophies 
primarily affecting the central 
nervous system 
G20-G26 Extrapyramidal and 
movement disorders 
G30-G32 Other degenerative 
diseases of the nervous system 
G35-G37 Demyelinating 
diseases of the central nervous 
system 
G60-64 Polyneuropathies 
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J40 = Bronchitis, not specified 
as acute or chronic 
J41 = Simple and mucopurulent 
chronic bronchitis 
J42 = Unspecified chronic 
bronchitis 
J43 = Emphysema 
J44 = Other chronic obstructive 
pulmonary disease 
J47 = Bronchiectasis 
J60-J70 Lung diseases due to 
external agents 
J80-J84 Other respiratory 
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J85-J86 Suppurative and 
necrotic conditions of lower 
respiratory tract 
J90-J94 Other diseases of pleura 
J95-J99 Other diseases of the 
respiratory system 
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 C22.0 hepatocellular carcinoma 
I85.0 Oesophageal varices 
I98.3 Oesophageal varices 
K70.2 Alcoholic fibrosis and 
sclerosis of liver 
K70.3 Alcoholic cirrhosis of liver 
K70.4 Alcoholic hepatic failure 
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fibrosis and cirrhosis of liver 
K72.0 Acute and subacute 
failure of the liver 
K72.1 Chronic hepatic failure 
K72.9 Hepatic coma 
K73 Chronic hepatitis, not 
elsewhere classified 
K74.0 Hepatic fibrosis 
K74.2 Hepatic fibrosis with 
hepatic sclerosis 
K74.3 Primary biliary cirrhosis 
K74.4 Secondary biliary cirrhosis 
K74.5 Biliary cirrhosis, 
unspecified 
K74.6 Other and unspecified 
cirrhosis of liver 
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 2.5.3 Adrenergic 
neurone blocking 
drugs 
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Any proton 
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 1.3.5 Proton pump 
inhibitors 
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Missing data imputation
We used the Amelia II package in R to impute missing values for continuous and categorical variables.[1] This
package uses an EMB (bootstrapped expectation maximization) algorithm for imputation under the assumption
that data are missing at random. Here we used it to generate 10 imputed datasets and for each individual the mean
of the imputed values across these 10 datasets was then used in subsequent analyses including the means of the
indicator (dummy) variables for categorical variables.
Selection of the functional form for continuous variables in the stepwise prediction model
We cannot assume that treating continuous variables as linear in regression will maximize prediction. We therefore
used the R package mfp to find the functional form for continuous variables being entered into the stepwise prediction
model.[2,3] Mfp uses a backwards elimination step with an adaptive algorithm to select the best fractional polynomial
transformation for each continuous variable. The resulting transformed variables were then made available to the
step procedure.
Further details of stepwise regression for building the prediction model for F-/CCU-COVID-19
For building the predictive model of F/CCU-COVID-19 we used stepwise regression, alternating between forward
and backward steps, implemented in the R function stats::step to select across the 35 variables listed in Table 2 as
well as terms for age:sex, age:diabetes type, sex:diabetes type. For variable selection the step function maximizes
the Akaike Information Criterion (AIC)[4]. The AIC is a trade off between the goodness of fit of a model and its
simplicity or sparsity. We set a stringent penalty of 4p -2 log likelihood where p is the number of parameters.
Assessment of model predictive performance
The predictive performance of the base model and then the model incremented with diabetes specific factors was
evaluated by 20-fold cross validation. The dataset was split randomly into 20 equal sized disjoint test folds. For
each test fold, the remaining observations constitute the training fold. The predictive performance of the model
learned on each training fold was then evaluated on the corresponding test fold. The predictive performance was
summarised over the entire dataset as the C-statistic and as the expected information for discrimination (lambda)
using the wevid package[5,6].
Sensitivity analyses of the final predictive model
We tested whether using a co-morbidity index (the Charlson Index)[7] rather than the individual co-morbidities
we considered improved prediction. In addition we evaluated whether an improved predictive performance was
obtained using a LASSO penalized regression but not forcing any baseline covariates into the model. We also tested
whether modelling only fatal cases resulted in any change in the variables selected or predictive performance.
Derivation of COVID-age
The risk prediction model for F/CCU-COVID-19, when applied to an individual with diabetes with any given
set of covariate values, outputs the logit of the probability (i.e. the log odds) of F/CCU-COVID-19 by 31st July
2020. For the Scottish population without diabetes, we fitted a generalised additive model (GAM) with a logistic
link function and binomial likelihood to the one-year age and sex-specific counts of F/CCU-COVID-19. This GAM
model returns the logit of probability of having developed F/CCU-COVID-19 by 31st July 2020 in the non-diabetic
population at any given age and sex and given the risk factor distribution in that population. The COVID-age for a
person with diabetes is then defined as the age at which the logit of the probability of disease in a non-diabetic
individual of the same sex equates to the logit of probability in the diabetic individual under study. To enable a user
to calculate this COVID-age for a person with diabetes and a given set of characteristics, we generated a Shiny
application located at https://diabepi.shinyapps.io/covidrisk/ (Online; Accessed 11th November 2020). The purpose
of the Shiny app to give the reader a sense of how individual risk factor profiles in those with diabetes translate into
elevated risks compared to those without diabetes.
[1]https://cran.r-project.org/web/packages/Amelia/vignettes/amelia.pdf Online; Accessed 11th November 2020
[2]https://cran.r-project.org/web/packages/mfp/mfp.pdf Online; Accessed 11th November 2020
[3]Sauerbrei W, Royston P (1999) Building multivariable prognostic and diagnostic models: transformation of the
predictors by using fractional polynomials. Journal of the Royal Statistical Society (Series A) 162: 71–94. Online;
Accessed 11th November 2020
[4] https://www.rdocumentation.org/packages/stats/versions/3.6.2/topics/step Online; Accessed 11th November
2020
[5] https://cran.r-project.org/web/packages/wevid/index.html Online; Accessed 11th November 2020
[6]McKeigue P. Quantifying performance of a diagnostic test as the expected information for discrimina-
tion:Relation to the C-statistic: Statistical Methods in Medical Research 2018. doi:10.1177/0962280218776989.
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[7]Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity
in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-
9681(87)90171-8. PMID: 3558716. Online; Accessed 11th November 2020
Supplemental results
Source of ascertainment of the cases
Supplement Figure 1 shows the source of ascertainment of the cases; Of all those with F/CCU-COVID-19, there
had been a positive test in 71% (768/1082), 3.6% (39/1082) were ascertained from hospital discharge without a prior
positive test and 25% (275/1082) were ascertained only from a COVID-19 mention on death certification. Almost
all those with any evidence of COVID-19 were evaluable for F/CCU-COVID-19 status in that there were only 26 of
those declared as not having had CCU or died that were still within 28 days of diagnosis by time of data extraction.
Of those defined as having had a COVID-19 death, just 8/963 were people who died within 28 days of diagnosis but
did not have a COVID-19 mention on death certificate.
Variable missingness
Only ethnicity (14.5%) and albuminuria (37.8%) had substantial missingness (Table 2). For continuous variables
missingness was as follows: HbA1c 6%, BMI 10%, SBP 7%, DBP 7%, Total cholesterol 9% BMI 10.2% (Supplement
Table 4). BMI was the only variable with substantial differences in missingness between those who did (17.4%) and
did not (10.2%) develop F/CCU-COVID-19.
Prediction model sensitivity analyses
Using LASSO regression gave a similar prediction performance to the step procedure (C-statistic 0.836) but was
much less sparse than the stepwise model therefore not the preferred model. Feeding the Charlson comorbidity index,
rather than each individual listed conditions, to the model did not improve prediction performance (C-statistic 0.841)
and was also less sparse. When the modelling was restricted to fatal cases only a similar pattern of associations




SCI-Diabetes : Scottish Care Information Diabetes system of clinical and network applications
NSAIDs : Non steroidal anti-inflammatory drugs
SGLT2 inhibitors : Sodium glucose transport 2 inhibitors
PPI : Proton pump inhibitors
ATC : Anatomical theraputical classification system
GLP1 : Glucagon-like peptide 1 agonists
DPP4 : Dipeptidyl peptidase-4
TZD : Thiazolidinediones
RRT : Renal replacement therapy
BMI : Body mass index
HbA1c : Glycated haemoglobin
eGFR : Estimated glomerular filtration rate
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Supplementary Figure 2: Relationship of BMI with F/CCU-COVID-19 as modelled by the ’mfp’ R package showing the estimated risk





















Supplementary Figure 3: ROC curve detailing sensitivity and specificity of the F/CCU-COVID-19 predictive model in people with
diabetes (C-statistic 0.85)
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Supplementary Figure 4: Calibration plot showing predicted versus observed risk of F/CCU-COVID-19 by decile of risk
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Supplementary Table 1: Risk of F/CCU-COVID-19 in the National population of Scotland age with and without diabetes by age band
and sex
Sex National Population 0-39 40-49 50-59 60-69 70-79 80+ Total
All No Diabetes (Total) 2576253 654864 733937 562011 395025 221861 5143951
All No Diabetes F/CCU-COVID-19 (N %) 104 (0.00%) 170 (0.03%) 374 (0.05%) 484 (0.09%) 817 (0.21%) 2132 (0.96%) 4081 (0.08%)
All Diabetes (Total) 23106 26026 60276 82126 79782 48033 319349
All Diabetes F/CCU-COVID-19 (N %) 5 (0.02%) 28 (0.11%) 78 (0.13%) 137 (0.17%) 310 (0.39%) 524 (1.09%) 1082 (0.34%)
Male No Diabetes (Total) 1298091 316511 348638 262021 174951 82305 2482517
No Diabetes F/CCU-COVID-19 (N %) 58 (0.00%) 93 (0.03%) 246 (0.07%) 308 (0.12%) 475 (0.27%) 859 (1.04%) 2039 (0.08%)
Diabetes (Total) 12317 15091 36077 49291 45274 22436 180486
Diabetes F/CCU-COVID-19 (N %) 2 (0.02%) 18 (0.12%) 52 (0.14%) 101 (0.20%) 209 (0.46%) 275 (1.23%) 657 (0.36%)
Female No Diabetes (Total) 1278162 338353 385299 299990 220074 139556 2661434
No Diabetes F/CCU-COVID-19 (N %) 46 (0.00%) 77 (0.02%) 128 (0.03%) 176 (0.06%) 342 (0.16%) 1273 (0.91%) 2042 (0.08%)
Diabetes (Total) 10789 10935 24199 32835 34508 25597 138863
Diabetes F/CCU-COVID-19 (N %) 3 (0.03%) 10 (0.09%) 26 (0.11%) 36 (0.11%) 101 (0.29%) 249 (0.97%) 425 (0.31%)
32











OR 2.5% 97.5% P-Value
All 1082 318267 4081 5139870 1.395 1.304 1.494 <0.001
Male 657 179829 2039 2480478 1.449 1.325 1.584 <0.001
Female 425 138438 2042 2659392 1.339 1.205 1.487 <0.001
All Aged < 60 111 109297 648 3964406 2.494 2.032 3.061 <0.001
All Aged 60-70 137 81989 484 561527 1.764 1.457 2.136 <0.001
All Aged 70+ 834 126981 2949 613937 1.327 1.227 1.434 <0.001
Other diabetes 23 8983 4081 5139870 1.262 0.836 1.905 0.268
Type 1 diabetes 51 34332 4081 5139870 2.396 1.815 3.163 <0.001
Type 2 diabetes 1008 274952 4081 5139870 1.369 1.276 1.468 <0.001
Associations were adjusted for age and sex, with the exception of sex, which was adjusted for age
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Supplementary Table 3: Characteristics of all those with type 1 diabetes in Scotland who did and did not develop F/CCU-COVID-19 by
31st July 2020
No F/CCU-COVID-19 F/CCU-COVID-19 Total diabetes population
Total included 34332(99.85) 51(0.15) 34383
Sociodemographic
Age (years) 44.5(29.7,58.3) 71.4(56.4,80.6) 44.5(29.7,58.3)
Diabetes duration (years) 19.5(9.6,30.6) 27.0(17.1,39.8) 19.5(9.6,30.6)
Carehome resident 194(0.6) 20(39.2) 214(0.6)
Deprivation index
Quintile 1 (most deprived) 6599(19.2) 13(25.5) 6612(19.2)
Quintile 2 6728(19.6) 13(25.5) 6741(19.6)
Quintile 3 6407(18.7) 8(15.7) 6415(18.7)
Quintile 4 6223(18.1) 5(9.8) 6228(18.1)
Quintile 5 (least deprived) 5768(16.8) 5(9.8) 5773(16.8)
Unknown 2607(7.6) 7(13.7) 2614(7.6)
Comorbidities
Any DKA admission in past 5 years 5015(14.6) 14(27.5) 5029(14.6)
Any hypoglycaemia admission in past 5yrs 2099(6.1) 15(29.4) 2114(6.1)
No. of other hospital admissions in past 5 years 1.0(0.0,2.0) 7.0(2.5,13.5) 1.0(0.0,2.0)
Any heart disease 4816(14.0) 31(60.8) 4847(14.1)
Asthma or chronic lower airway disease 8680(25.3) 24(47.1) 8704(25.3)
Neurological and dementia (excluding epilepsy) 1378(4.0) 12(23.5) 1390(4.0)
Liver disease 160(0.5) 0(0.0) 160(0.5)
Immune disease or on immunosuppressants 626(1.8) 3(5.9) 629(1.8)
Any listed condition 12155(35.4) 43(84.3) 12198(35.5)
Other clinical measures
Insulin pump use 4811(14.0) 1(2.0) 4812(14.0)
Flash glucose monitor use 11711(34.1) 6(11.8) 11717(34.1)
HbA1c (mmol/mol) 67(57,79) 69(57,87) 67(57,79)
BMI (kg/m2) 26(23,30) 27(24,32) 26(23,30)
Systolic BP (mmHg) 130(120,140) 132(124,143) 130(120,140)
Diastolic BP (mmHg) 76(70,82) 72(65,80) 76(70,82)
Total cholesterol (mmol/L) 4(4,5) 4(4,5) 4(4,5)
eGFR (mL/min/1.73m2) 100(83,116) 72(44,87) 100(83,116)
Albuminuric status
Normal 13076(38.1) 16(31.4) 13092(38.1)
Micro 4300(12.5) 10(19.6) 4310(12.5)
Macro 1121(3.3) 4(7.8) 1125(3.3)
Unknown 15835(46.1) 21(41.2) 15856(46.1)
Retinopathy
None 11384(33.2) 21(41.2) 11405(33.2)
Non referable 9101(26.5) 11(21.6) 9112(26.5)
Referable / eye clinic 7272(21.2) 14(27.5) 7286(21.2)
Unknown 6575(19.2) 5(9.8) 6580(19.1)
Tobacco smoking status
Current smoker 6195(18.0) 7(13.7) 6202(18.0)
Ex smoker 12555(36.6) 26(51.0) 12581(36.6)
Never smoked 13869(40.4) 17(33.3) 13886(40.4)
Unknown 1713(5.0) 1(2.0) 1714(5.0)
Drug exposures
Lipid lowering 13038(38.0) 37(72.5) 13075(38.0)
Proton Pump Inhibitors 8574(25.0) 23(45.1) 8597(25.0)
NSAIDS 11238(32.7) 32(62.7) 11270(32.8)
Anti-coagulants anti-platelets 5909(17.2) 33(64.7) 5942(17.3)
Antihypertensives (any) 12070(35.2) 30(58.8) 12100(35.2)
Number of ATC level 3 drug classes (excluding
DM)
5.0(2.0,9.0) 12.0(9.5,14.5) 5.0(2.0,9.0)
Data are shown in N(%) for categorical values and median interquartile range for continuous values
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Supplementary Table 4: Characteristics of all those with type 2 diabetes in Scotland who did and did not develop F/CCU-COVID-19 by
31st July 2020
No F/CCU-COVID-19 F/CCU-COVID-19 Total diabetes population
Total included 274952(99.63) 1008(0.37) 275960
Sociodemographic
Age (years) 68.4(59.1,76.8) 80.2(72.2,86.1) 68.4(59.1,76.9)
Diabetes duration (years) 10.0(5.5,15.6) 13.3(7.9,18.6) 10.1(5.5,15.6)
Carehome resident 5556(2.0) 367(36.4) 5923(2.1)
Deprivation index
Quintile 1 (most deprived) 64494(23.5) 302(30.0) 64796(23.5)
Quintile 2 62407(22.7) 246(24.4) 62653(22.7)
Quintile 3 55191(20.1) 178(17.7) 55369(20.1)
Quintile 4 48364(17.6) 163(16.2) 48527(17.6)
Quintile 5 (least deprived) 39189(14.3) 95(9.4) 39284(14.2)
Unknown 5307(1.9) 24(2.4) 5331(1.9)
Comorbidities
Any DKA admission in past 5 years 1320(0.5) 8(0.8) 1328(0.5)
Any hypoglycaemia admission in past 5yrs 3391(1.2) 52(5.2) 3443(1.2)
No. of other hospital admissions in past 5 years 1.0(0.0,3.0) 5.0(2.0,10.0) 1.0(0.0,3.0)
Any heart disease 93240(33.9) 651(64.6) 93891(34.0)
Asthma or chronic lower airway disease 93237(33.9) 467(46.3) 93704(34.0)
Neurological and dementia (excluding epilepsy) 13246(4.8) 214(21.2) 13460(4.9)
Liver disease 2671(1.0) 27(2.7) 2698(1.0)
Immune disease or on immunosuppressants 3143(1.1) 18(1.8) 3161(1.1)
Any listed condition 148979(54.2) 833(82.6) 149812(54.3)
Other clinical measures
HbA1c (mmol/mol) 56(48,68) 57(47,70) 56(48,68)
BMI (kg/m2) 31(27,35) 29(25,33) 31(27,35)
Systolic BP (mmHg) 134(125,142) 132(122,142) 134(125,142)
Diastolic BP (mmHg) 77(70,82) 74(67,80) 77(70,82)
Total cholesterol (mmol/L) 4(4,5) 4(3,5) 4(4,5)
eGFR (mL/min/1.73m2) 82(64,95) 63(45,81) 82(64,95)
Albuminuric status
Normal 114978(41.8) 279(27.7) 115257(41.8)
Micro 49925(18.2) 221(21.9) 50146(18.2)
Macro 10008(3.6) 72(7.1) 10080(3.7)
Unknown 100041(36.4) 436(43.3) 100477(36.4)
Retinopathy
None 183660(66.8) 584(57.9) 184244(66.8)
Non referable 38540(14.0) 145(14.4) 38685(14.0)
Referable / eye clinic 20436(7.4) 118(11.7) 20554(7.4)
Unknown 32316(11.8) 161(16.0) 32477(11.8)
Tobacco smoking status
Current smoker 42650(15.5) 101(10.0) 42751(15.5)
Ex smoker 137003(49.8) 641(63.6) 137644(49.9)
Never smoked 94352(34.3) 262(26.0) 94614(34.3)
Unknown 947(0.3) 4(0.4) 951(0.3)
Drug exposures
Lipid lowering 193144(70.2) 754(74.8) 193898(70.3)
Proton Pump Inhibitors 119879(43.6) 541(53.7) 120420(43.6)
NSAIDS 128843(46.9) 650(64.5) 129493(46.9)
Anti-coagulants anti-platelets 104534(38.0) 621(61.6) 105155(38.1)
Antihypertensives (any) 181786(66.1) 668(66.3) 182454(66.1)
Number of ATC level 3 drug classes (excluding
DM)
8.0(5.0,12.0) 11.0(8.0,15.0) 8.0(5.0,12.0)
Number of DM drug classes prescribed 1.0(1.0,2.0) 1.0(1.0,2.0) 1.0(1.0,2.0)
Data are shown in N(%) for categorical values and median interquartile range for continuous values
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Supplementary Table 5: Additional characteristics described in categories and showing missingness and detailed drug exposures of all
those with diabetes in Scotland who did and did not develop F/CCU-COVID-19 by 31st July 2020
No F/CCU-COVID-19 F/CCU-COVID-19 Total diabetes population
HbA1c (mmol/mol)
<53 116898(36.7) 421(38.9) 117319(36.7)
53-58 40527(12.7) 110(10.2) 40637(12.7)
>58-75 86790(27.3) 289(26.7) 87079(27.3)
>75-85 24963(7.8) 83(7.7) 25046(7.8)
>85 29852(9.4) 126(11.6) 29978(9.4)
Unknown 19237(6.0) 53(4.9) 19290(6.0)
BMI (kg/m2)
<20 6262(2.0) 55(5.1) 6317(2.0)
20-25 40604(12.8) 185(17.1) 40789(12.8)
>25-30 91486(28.7) 280(25.9) 91766(28.7)
>30-35 79407(24.9) 209(19.3) 79616(24.9)
>35-40 40444(12.7) 101(9.3) 40545(12.7)
>40 27615(8.7) 64(5.9) 27679(8.7)
Unknown 32449(10.2) 188(17.4) 32637(10.2)
eGFR (mL/min/1.73m2)
<30 or RRT 7620(2.4) 96(8.9) 7716(2.4)
30-60 50543(15.9) 386(35.7) 50929(15.9)
>60-90 126804(39.8) 438(40.5) 127242(39.8)
>90 111661(35.1) 141(13.0) 111802(35.0)
Unknown 21639(6.8) 21(1.9) 21660(6.8)
Systolic blood pressure (mmHg)
<130 121838(38.3) 473(43.7) 122311(38.3)
130-160 160235(50.3) 486(44.9) 160721(50.3)
>160 13742(4.3) 64(5.9) 13806(4.3)
Unknown 22452(7.1) 59(5.5) 22511(7.0)
Diastolic blood pressure (mmHg)
≤80 207412(65.2) 820(75.8) 208232(65.2)
>80 88392(27.8) 202(18.7) 88594(27.7)
Unknown 22463(7.1) 60(5.5) 22523(7.1)
Total cholesterol (mmol/L)
≤5 222234(69.8) 770(71.2) 223004(69.8)
>5 66874(21.0) 180(16.6) 67054(21.0)
Unknown 29159(9.2) 132(12.2) 29291(9.2)
Drug exposures
Diabetes drugs
Insulin 68811(21.6) 270(25.0) 69081(21.6)
Biguanides 194242(61.0) 631(58.3) 194873(61.0)
Sulfonylureas 83950(26.4) 361(33.4) 84311(26.4)
TZD’s 13363(4.2) 44(4.1) 13407(4.2)
Acarbose 192(0.1) 1(0.1) 193(0.1)
DPP4 inhibitors 49404(15.5) 184(17.0) 49588(15.5)
GLP1 agonists 17539(5.5) 53(4.9) 17592(5.5)
SGLT2 inhibitors 41432(13.0) 96(8.9) 41528(13.0)
Antihypertensive drugs
Vasodilator 26915(8.5) 52(4.8) 26967(8.4)
Central acting 3037(1.0) 10(0.9) 3047(1.0)
Alpha adrenergic 19194(6.0) 67(6.2) 19261(6.0)
Angiotensin inhibitor 124024(39.0) 449(41.5) 124473(39.0)
Angiotensin antagonist 47644(15.0) 149(13.8) 47793(15.0)
Renin inhibitor 7(0.0) 0(0.0) 7(0.0)
Thiazides 47158(14.8) 129(11.9) 47287(14.8)
Calcium channel blocker 89539(28.1) 340(31.4) 89879(28.1)
Data are shown in N(%) for categorical values and median interquartile range for continuous values
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Supplementary Table 6: Logistic regression of association of additional categories and drug exposures with F/CCU-COVID-19 in people
with diabetes. Associations were adjusted for age, sex, diabetes duration and type.
Predictor Odds Ratio 95%CI P-Value
HbA1c (mmol/mol) (global) <0.001
<53 1 (reference)
53-58 0.808 (0.660, 0.988) 0.037
>58-75 1.073 (0.923, 1.246) 0.359
>75-85 1.302 (1.023, 1.655) 0.032
>85 2.065 (1.682, 2.536) <0.001
BMI (kg/m2) (global) <0.001
<20 2.403 (1.773, 3.259) <0.001
20-25 1 (reference)
>25-30 0.801 (0.671, 0.956) 0.014
>30-35 0.928 (0.772, 1.115) 0.425
>35-40 0.966 (0.758, 1.229) 0.776
>40 1.191 (0.888, 1.597) 0.244
eGFR (mL/min/1.73m2) (global) <0.001
<30 or RRT 2.372 (1.761, 3.194) <0.001
30-60 1.320 (1.040, 1.675) 0.022
>60-90 0.980 (0.794, 1.210) 0.849
>90 1 (reference)
Systolic BP (mmHg) (global) <0.001
<130 1 (reference)
130-160 0.655 (0.578, 0.741) <0.001
>160 0.862 (0.662, 1.121) 0.267
Diastolic BP (mmHg) (global) 0.776
≤80 1 (reference)
>80 0.978 (0.836, 1.143) 0.776
Total cholesterol (mmol/L) (global) 0.119
≤5 1 (reference)
>5 1.140 (0.969, 1.341) 0.114
Diabetes drugs
Biguanides 1.051 (0.925, 1.195) 0.446
Insulin 1.964 (1.670, 2.309) <0.001
Sulfonylureas 1.310 (1.149, 1.492) <0.001
TZD’s 0.898 (0.662, 1.218) 0.488
Acarbose 1.078 (0.150, 7.729) 0.941
DPP4 inhibitors 1.092 (0.929, 1.283) 0.286
GLP1 agonists 1.407 (1.059, 1.868) 0.018
SGLT2 inhibitors 1.124 (0.904, 1.398) 0.293
Antihypertensive drugs
Vasodilator 0.680 (0.511, 0.905) 0.008
Central acting 1.256 (0.672, 2.349) 0.476
Alpha adrenergic 0.746 (0.582, 0.957) 0.021
Angiotensin inhibitor 0.951 (0.842, 1.075) 0.421
Angiotensin antagonist 0.721 (0.606, 0.857) <0.001
Thiazides 0.615 (0.512, 0.740) <0.001
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Type 2 diabetes 0.00000000000000
Type 1 diabetes 0.11245287638435
Other diabetes types -0.14409417993123
Diabetes duration (years) -0.00209419600062
Carehome resident 2.38217027053367
Deprivation quintile 1 (most deprived) 0.00000000000000
Deprivation quintile 2 -0.16490767973292
Deprivation quintile 3 -0.48028099889677
Deprivation quintile 4 -0.42229894439757
Deprivation quintile 5 (least deprived) -0.72620380743347
log(No. of other hospital admissions + 1 (5yrs)) 0.46662994412763





Systolic BP (mmHg) -0.00567062648956
Any antihypertensive -0.23298518580490
Number of DM drug classes prescribed 0.06281305073017
Number of ATC level 3 drug classes (excluding DM) 0.02632838543546
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